Tag: FDA

Xenotransplantation: Argentina is about to produce genetically modified animals for human transplants

While the international medical community celebrates the first successful xenotransplantation, in Argentina two research teams from public universities are preparing to produce genetically modified animals so that their organs are suitable for human transplants and the first pigs of this type would be obtained at the end of this year…

Continue Reading Xenotransplantation: Argentina is about to produce genetically modified animals for human transplants

Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of Non-Hodgkin’s lymphoma in the United States, with approximately 40% of first-line DLBCL chemoimmunotherapy attempts failing. The FDA approved a new type of antibody-drug conjugate (ADC), Zynlonta (loncastuximab tesirine), once called ADCT-402, on April 23, 2021, for relapsed or…

Continue Reading Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma

Guardant Health Staff Site Reliability Engineering / DevOps: Bioinformatics

Covid Vaccination Policy:  Starting January 7, 2022, Guardant Health will require all employees to be fully vaccinated to either (a) establish that they have been fully vaccinated against COVID-19; or (b) request and obtain an approved exemption from Guardant’s COVID-19 U.S. Vaccination Policy as a reasonable accommodation, as consistent with applicable…

Continue Reading Guardant Health Staff Site Reliability Engineering / DevOps: Bioinformatics

Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

This story originally appeared on Zacks Editas Medicine, Inc. EDIT has made rapid progress in the development of its lead pipeline candidate, EDIT-101, which employs CRISPR gene editing, to treat Leber congenital amaurosis type 10 (LCA10) — a rare genetic illness that causes blindness. – Zacks The company is evaluating…

Continue Reading Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

FDA Grants Regenerative Medicine Advanced Therapy, Fast Track Designations to Novel CAR T-Cell Therapy for Relapsed, Refractory B-cell Non-Hodgkin Lymphoma

C-CAR039 showed positive efficacy and safety data in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Officials with the FDA have granted both Regenerative Medicine Advanced Therapy (RMAT) Designation and Fast Track Designation to C-CAR039, a novel autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients…

Continue Reading FDA Grants Regenerative Medicine Advanced Therapy, Fast Track Designations to Novel CAR T-Cell Therapy for Relapsed, Refractory B-cell Non-Hodgkin Lymphoma

Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare … | News

– Fast Track Designation granted from U.S. Food and Drug Administration for PRA023 for the treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) – – New patent granted for PRA023 companion diagnostic (CDx) reinforces Prometheus’ precision approach and extends CDx patent coverage into 2040 – – Company to present today…

Continue Reading Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare … | News

Basilea reports on portfolio progress made in 2021

Achieved important Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) milestones Added new clinical candidate BAL0891 to oncology pipeline and advanced clinical programs with derazantinib and lisavanbulin Basel, January 06, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases…

Continue Reading Basilea reports on portfolio progress made in 2021

Citius Pharmaceuticals, Inc. to Present at Upcoming Virtual Conferences

H.C. Wainwright BioConnect 2022 Conference January 10-13, 2022 Biotech Showcase Virtual Conference January 17-19, 2022 CRANFORD, N.J., Jan. 4, 2022 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on…

Continue Reading Citius Pharmaceuticals, Inc. to Present at Upcoming Virtual Conferences

Sr. Manager of Manufacturing – Resumetojobs.com

NuProbe USA is seeking an experienced Sr. Manager, In-Vitro Diagnostics Operations who will be responsible for all aspects of manufacturing, including design transfer of newly developed products from research & development. The successful candidate will control production planning, scheduling and forecasting. The candidate will lead continuous improvements in manufacturing as…

Continue Reading Sr. Manager of Manufacturing – Resumetojobs.com

Illumina MiSeq Instruments Preventative Maintenance

From: Federal Government(Federal) Start Date 27 May, 2021 (7 months ago) Due Date 07 Jun, 2021 (6 months ago) Opportunity Type Bid Notification Opportunity Identifier FDA-CSS-1241810 Customer / Agency HEALTH AND HUMAN SERVICES, DEPARTMENT OF Location Jefferson , AR 72079 USA Illumina MiSeq Instruments Preventative Maintenance per the attached Combined…

Continue Reading Illumina MiSeq Instruments Preventative Maintenance

Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

Introduction Most cases of pancreatic adenocarcinoma (PDAC) are diagnosed in the metastatic or locally advanced stage. It is the fourth leading cause of cancer death in the United States,1,2 with a 5-year overall survival (OS) around 10% in this country2 despite years of research and therapeutic development. For those patients…

Continue Reading Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

Brem Looks at Multiple Treatments for Patients With DLBCL

During a Targeted OncologyTM Case-Based Roundtable event, Elizabeth A. Brem, MD, an assistant professor in Division of Hematology/Oncology, Department of Medicine at UC Irvine Health in Los Angeles, CA, moderated a discussion about a 43-year-old woman with diffuse large B-cell lymphoma. Targeted Oncology™: What therapeutic options would you consider at…

Continue Reading Brem Looks at Multiple Treatments for Patients With DLBCL

Bioinformatics Engineer/Senior Engineer – Cambridge Massachusetts

Flagship Pioneering has launched a privately held, biotechnology company that is pioneering novel diagnostics for cancer. This new company, Harbinger Oncology, is a highly dynamic, entrepreneurial, and innovation-driven organization seeking to hire a Bioinformatics Engineer/Senior Engineer to join our team. Flagship Pioneering conceives, creates, resources, and grows first-in-category life sciences…

Continue Reading Bioinformatics Engineer/Senior Engineer – Cambridge Massachusetts

Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab

Introduction Rituximab (Rituxan; Genentech) is a chimeric anti-CD20 monoclonal antibody widely used in non-Hodgkin lymphoma (NHL) treatment.1 Worldwide, rituximab is recommended for a variety of B-cell malignancies,1,2 and it has a well-established efficacy and safety profile, with more than 4 million patients treated.1,3 In the United States, rituximab is approved…

Continue Reading Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab

Guardant Health Senior DevOps Engineer: Bioinformatics

Covid Vaccination Policy:  Starting January 7, 2022, Guardant Health will require all employees to be fully vaccinated to either (a) establish that they have been fully vaccinated against COVID-19; or (b) request and obtain an approved exemption from Guardant’s COVID-19 U.S. Vaccination Policy as a reasonable accommodation, as consistent with applicable…

Continue Reading Guardant Health Senior DevOps Engineer: Bioinformatics

Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia

EDIT-301 is in development as a transformative, one-time treatment for people living with transfusion-dependent beta thalassemia Editas Medicine will initiate a Phase 1/2 clinical trial in 2022 CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S….

Continue Reading Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia

About: Pemigatinib

dbo:abstract Pemigatinib (INN), sold under the brand name Pemazyre, is a medication for the treatment of adults with previously treated, unresectable locally advanced or metastatic bile duct cancer (cholangiocarcinoma) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. Pemigatinib works by…

Continue Reading About: Pemigatinib

Very important pharmacogene variants in the Blang population

Introduction The use of drugs should be different among diverse ethnic groups because of differences in ethnicity, age, sex, environmental factors and genetic factors. If these differences are ignored, then drug sensitivity, metabolic rate, and adverse reactions are affected, which influences the curative effect of drugs and aggravates the illness…

Continue Reading Very important pharmacogene variants in the Blang population

Human microRNA inhibits expression of pathogenic gene underlying facioscapulohumeral muscular dystrophy

Fig. 1: miR-675 targets the DUX4 ORF and 3′UTR. a RenLuc-DUX4-FL dual-luciferase reporter and CMV.H19 constructs, and U6.MIR675, H1.MIR675, U6.MIR675-3p, and U6.MIR675-5p miRNAs. RenLuc-DUX4-FL contains DUX4 ORF and 3′UTR sequences fused to Renilla luciferase after the stop codon. Exons 1–3 are indicated (Ex1,2,3). *SD5 indicates silent mutation of a cryptic…

Continue Reading Human microRNA inhibits expression of pathogenic gene underlying facioscapulohumeral muscular dystrophy

Fate Therapeutics Highlights Positive Durability of

6 of 10 Patients Naïve to Treatment with Autologous CAR T-cell Therapy Continue in Ongoing Response at Median Follow-up of 9.1 Months, including 4 Patients with >6 Months Follow-up, at ≥90 Million FT516 Cells per Dose 3 of 8 Patients Previously Treated with Autologous CAR T-cell Therapy Achieve Complete Response…

Continue Reading Fate Therapeutics Highlights Positive Durability of

Real-World Study of Tisagenlecleucel in R/R B-Cell Non-Hodgkin Lymphomas Shows Efficacy, Safety

Real-world data on tisagenlecleucel in patients with relapsed/refractory B-cell lymphoma was consistent with the phase 2 JULIET trial, demonstrating favorable efficacy and safety. Real-world data on the use of tisagenlecleucel (Kymriah) showed greater efficacy and a favorable safety profile, according to updated findings from a study of the Center for…

Continue Reading Real-World Study of Tisagenlecleucel in R/R B-Cell Non-Hodgkin Lymphomas Shows Efficacy, Safety

CAR-T therapy trials show promise for earlier use in lymphoma

Cell therapy, a relatively new and expensive treatment for certain blood cancers, might soon dislodge a decades-old standard of care for people with a common type of lymphoma that’s returned after initial drugs fail. Results from two late-stage studies, presented over the weekend at the American Society of Hematology’s annual…

Continue Reading CAR-T therapy trials show promise for earlier use in lymphoma

Tafasitamab and Lenalidomide Combo Yields Higher OS vs Standard Options in Relapsed/Refractory DLBCL

Treatment with tafasitamab (Monjuvi) and lenalidomide (Revlimid) provided an overall survival (OS) benefit vs standard options in a population of patients with autologous stem cell transplant (ASCT)–ineligible relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to findings from an expanded analysis of RE-MIND2 study (NCT04697160) that was presented at the 2021…

Continue Reading Tafasitamab and Lenalidomide Combo Yields Higher OS vs Standard Options in Relapsed/Refractory DLBCL

DGAP-News: ???????MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL

​​​​​​​MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL 11.12.2021 / 18:00 The issuer is solely responsible for the content of this announcement. MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of…

Continue Reading DGAP-News: ???????MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL

Natera launches Prospera with quantification to improve kidney graft rejection testing

Natera has announced the launch of Prospera with quantification, the only cell-free DNA (cfDNA) test for kidney rejection that provides three values—the quantity of donor-derived cfDNA (dd-cfDNA), fraction of dd-cfDNA, and total cfDNA—on every report. Combining these three metrics has been shown to improve sensitivity when evaluating transplant rejection, compared…

Continue Reading Natera launches Prospera with quantification to improve kidney graft rejection testing

Sr Scientist – IVD Development – Houston

NuProbe USA Inc . is looking for a Staff/Senior Scientist to lead the IVD project development program at NuProbe to support both research and in vitro diagnostic (IVD) assays for use in medical research, clinical trials, regulatory submissions, and clinical diagnostic use.  NuProbe USA is a rapidly growing company and…

Continue Reading Sr Scientist – IVD Development – Houston

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The MarketWatch News Department was not involved in the creation of this content. December 11, 2021 (ACCESSWIRE via COMTEX) — – RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies – Results from the retrospective cohort analysis indicate significant overall survival improvement…

Continue Reading MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

EFS improvement with axi-cel CAR-T a ‘breakthrough’ in second-line treatment of DLBCL

December 11, 2021 3 min read Source/Disclosures Published by: Source: Locke FL, et al. Abstract 2. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021. Disclosures: Kite Pharma sponsored this study. Leslie reports advisory board, consultant or speakers bureau roles with AbbVie, AstraZeneca, BeiGene, Celgene/Bristol Myers…

Continue Reading EFS improvement with axi-cel CAR-T a ‘breakthrough’ in second-line treatment of DLBCL

Tafasitamab/Lenalidomide Improves OS Over Other Options in Retrospective Relapsed/Refractory DLBCL

The combination of tafasitamab (Monjuvi) and lenalidomide (Revlimid) prolonged median overall survival (OS) compared with other standard options for autologous stem cell transplant (ASCT)-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a closely matched expanded analysis of the observational, retrospective RE-MIND2 (NCT04697160) study presented at the…

Continue Reading Tafasitamab/Lenalidomide Improves OS Over Other Options in Retrospective Relapsed/Refractory DLBCL

Liquid Biopsy Noninferior to Tissue-Based Genotyping in Management of Advanced NSCLC

Cell-free circulating tumor DNA (cfDNA)–based tumor genotyping was found to be noninferior to standard-of-care tissue-based genotyping for detection of guideline-recommended biomarkers and therapeutic outcomes in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). Cell-free circulating tumor DNA (cfDNA)–based tumor genotyping is noninferior to tissue-based genotyping for detection of guideline-recommended…

Continue Reading Liquid Biopsy Noninferior to Tissue-Based Genotyping in Management of Advanced NSCLC

The Evolving Treatment Landscape of Cholangiocarcinoma

Recent genomic profiling studies revealed that approximately 40% of patients with biliary tract cancers harbor actionable genomic mutations. The advances in the understanding and characterization of biliary tract cancers (BTCs), particularly intrahepatic cholangiocarcinoma (iCCA), and genomic profiling over the past decade have led to a rapid expansion of available treatment…

Continue Reading The Evolving Treatment Landscape of Cholangiocarcinoma

Pola-G-Len Regimen Shows Promise as an Alternative to CAR T Cells in Refractory FL

The combination of obinutuzumab (Gazyva) with polatuzumab vedotin (Polivy) or lenalidomide (Revlimid; Pola-G-Len) achieved high responses in patients with heavily pretreated refractory follicular lymphoma (FL) in a phase 1b/2 clinical trial. “Our findings demonstrated that the regimen of Pola-G-Len was safe and had a high level of activity in relapsed…

Continue Reading Pola-G-Len Regimen Shows Promise as an Alternative to CAR T Cells in Refractory FL

Qiagen (QGEN) Collaborates with Denovo to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. QIAGEN (NYSE: QGEN) and Denovo Biopharma LLC today announced a collaboration to develop a blood-based companion diagnostic (CDx) test to identify patients expressing Denovo Genomic Marker 1 (DGM1TM) who…

Continue Reading Qiagen (QGEN) Collaborates with Denovo to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL

Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

– QIAGEN’s blood-based test will help to identify patients with Diffuse Large B-Cell Lymphoma (DLBCL) likely to respond to Denovo’s new investigational cancer treatment DB102 – The partners seek FDA premarket approval (PMA) of the companion diagnostic test in tandem with the new drug application (NDA) approval. SAN DIEGO and…

Continue Reading Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

Qiagen And Denovo Biopharma Partner To Develop Companion Diagnostic Test For Treatment Of Diffuse Large B-Cell Lymphoma

Qiagen And Denovo Biopharma Partner To Develop Companion Diagnostic Test For Treatment Of Diffuse Large B-Cell Lymphoma Published: 12/09/2021 14:36 GMT Qiagen NV (QGEN) – Denovo Biopharma and Qiagen Partner to Develop Companion Diagnostic Test for Treatment of Diffuse Large B-cell Lymphoma (dlbcl).Partners Seek FDA Premarket Approval (pma) of Companion…

Continue Reading Qiagen And Denovo Biopharma Partner To Develop Companion Diagnostic Test For Treatment Of Diffuse Large B-Cell Lymphoma

Qiagen, Denovo Biopharma Partner To Develop Companion Diagnostic Test

Published: 12/09/2021 06:38 GMT Qiagen NV (QGEN) – Qiagen and Denovo Biopharma Partner to Develop Companion Diagnostic Test for Treatment of Diffuse Large B-cell Lymphoma (dlbcl).Qiagen’s Blood-based Test Will Help to Identify Patients With Diffuse Large B-cell Lymphoma (dlbcl) Likely to Respond to Denovo’s New Investigational Cancer Treatment Db102tm.Partners Seek…

Continue Reading Qiagen, Denovo Biopharma Partner To Develop Companion Diagnostic Test

QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

QIAGEN’s blood-based test will help to identify patients with Diffuse Large B-Cell Lymphoma (DLBCL) likely to respond to Denovo’s new investigational cancer treatment DB102TM The partners seek FDA premarket approval (PMA) of the companion diagnostic test in tandem with the new drug application (NDA) approval. New master collaboration agreement adds…

Continue Reading QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

Next Generation Sequencing Industry to Cross $34.8 Billion by 2027

DUBLIN, Dec. 8, 2021 /PRNewswire/ — The “Next Generation Sequencing Market, Global Forecast, Impact of COVID-19, Industry Trends, Growth, Opportunity By Types of Test, Company Analysis” report has been added to ResearchAndMarkets.com‘s offering. According to the report, the Global Next Generation Sequencing Market will reach US$ 34.8 Billion by 2027….

Continue Reading Next Generation Sequencing Industry to Cross $34.8 Billion by 2027

Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition

FLORHAM PARK, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced a poster presentation featuring data from the company’s ongoing Phase 2 CLOVER-1 study of…

Continue Reading Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition

Data Demonstrates Lucence Liquid Biopsy Test Can Track Treatment-Based ctDNA Changes

NEW YORK – At the European Society for Medical Oncology Congress this week, precision oncology assay developer Lucence presented data that demonstrated its amplicon-based LiquidHallmark assay could be used to personalize care for people with advanced urothelial carcinoma. LiquidHallmark is a laboratory-developed test based on the company’s AmpliMark next-generation sequencing platform…

Continue Reading Data Demonstrates Lucence Liquid Biopsy Test Can Track Treatment-Based ctDNA Changes

Salmonella outbreak detected in half of US states

The Centers for Disease Control and Prevention (CDC) warned Friday that an outbreak of salmonella due to an “unknown food source” has been detected in 25 states across the U.S. The agency said that on Sept. 2, it identified an outbreak of 20 salmonella oranienburg infections and that, since then,…

Continue Reading Salmonella outbreak detected in half of US states

HIV Cure Made On CRISPR Technology Gets FDA Approval For Human Trials

We could soon be very close to a cure for HIV as a CRISPR-Cas9 gene editing tech that showed success in mice is now approved for undergoing clinical trials on humans.  Reuters Also Read: No Child Will Ever Be Born Blind, If CRISPR Gene Editing Trials Work 100% In Humans The…

Continue Reading HIV Cure Made On CRISPR Technology Gets FDA Approval For Human Trials

MUSC and Helix launch In Our DNA SC, first-of-its-kind population genomics program to drive preventive, precision health care for South Carolinians | MUSC

Large-scale initiative will advance innovative research, improved health outcomes CHARLESTON, S.C. and SAN MATEO, Calif., (Sept. 20, 2021) – The Medical University of South Carolina  (MUSC) and Helix have announced a strategic collaboration to develop a first-of-its-kind population genomics initiative in South Carolina called In Our DNA SC. The large-scale program is designed…

Continue Reading MUSC and Helix launch In Our DNA SC, first-of-its-kind population genomics program to drive preventive, precision health care for South Carolinians | MUSC

Persistent Systems hiring Bioinformatics Data Scientist – South SFO, CA in Santa Clara, California, United States

About PersistentWe are a trusted Digital Engineering and Enterprise Modernization partner, combining deep technical expertise and industry experience to help our clients anticipate what’s next. Our offerings and proven solutions create unique competitive advantage for our clients by giving them the power to see beyond and rise above. We are…

Continue Reading Persistent Systems hiring Bioinformatics Data Scientist – South SFO, CA in Santa Clara, California, United States

Zika Vax in the Works; STI Guidelines Updated

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center in El Paso, look at the top medical stories of the week. This week’s topics include screening…

Continue Reading Zika Vax in the Works; STI Guidelines Updated

Mystery Salmonella Oranienburg Outbreak strikes 127 in 25 states

Likely linked to restaurant exposures – Texas hardest hit. On September 2, 2021, CDC identified an outbreak of 20 Salmonella Oranienburg infections. Since then, the outbreak has grown rapidly. As of September 15, 2021, 127 people infected with the outbreak strain of Salmonella Oranienburg have been reported from 25 states….

Continue Reading Mystery Salmonella Oranienburg Outbreak strikes 127 in 25 states

FDA clears IND application for CRISPR-edited T-cell receptor therapy to treat AML

September 17, 2021 1 min read ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process…

Continue Reading FDA clears IND application for CRISPR-edited T-cell receptor therapy to treat AML

Intellia Therapeutics Set to Enter Clinic with First Solo Ex Vivo Candidate

Courtesy Intellia Therapeutics Intellia Therapeutics is celebrating another first today as the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for NTLA-5001, its first wholly-owned ex vivo CRISPR genome editing candidate. NTLA-5001 is being developed for the treatment of acute myeloid leukemia (AML). Intellia…

Continue Reading Intellia Therapeutics Set to Enter Clinic with First Solo Ex Vivo Candidate

Excision’s CRISPR gene editing therapy for HIV is heading into human testing after FDA clearance

A CRISPR-Cas9 gene editing technology that has shown promise in clearing HIV from mice is headed into human testing. Excision BioTherapeutics will usher the CRISPR-based therapy EBT-101 into clinical trials after the FDA cleared an investigational new drug application, according to the company’s press release. EBT-101 is under development as…

Continue Reading Excision’s CRISPR gene editing therapy for HIV is heading into human testing after FDA clearance

The 13 health care leaders on the list

Time this week released its “100 Most Influential People” list, which includes a number of individuals who have made major contributions to health care. The 10 ‘most influential’ health care companies, according to TIME The list This year, TIME recognized several health care providers, scientists, public health officials, and advocates for their…

Continue Reading The 13 health care leaders on the list

Motif FoodWorks to launch myoglobin, a yeast-derived heme-binding protein delivering the ‘flavor and aroma of real meat’

According to the GRAS determination​​ (submitted in April and currently pending with the FDA), the myoglobin preparation – supplied as a frozen liquid – is intended for use at inclusion rates of ≤2%, to “mimic flavors associated with cooked ground meat​” in fresh or frozen plant-based burgers, patties, sausages, and other…

Continue Reading Motif FoodWorks to launch myoglobin, a yeast-derived heme-binding protein delivering the ‘flavor and aroma of real meat’

San Diego scientists race to treat rare genetic diseases

Connor Dalby is in many ways your typical 12-year-old boy. He loves dipping his feet in the cool of the ocean and cruising on his bike through his Oceanside neighborhood. He’s mischievous, and he’s got a way of sticking out his chin and grinning madly when goofing off, blue eyes…

Continue Reading San Diego scientists race to treat rare genetic diseases

FDA approves first trial investigating CRISPR gene editing as HIV cure

The US Food and Drug Administration (FDA) has given the nod for Excision BioTherapeutics to begin trials testing CRISPR gene editing as a treatment for HIV. EBT-101 will be a first-in-human, CRISPR-based one-time gene therapy to be evaluated in individuals with HIV. On 15 September Excision announced that the FDA…

Continue Reading FDA approves first trial investigating CRISPR gene editing as HIV cure

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia | DNA RNA and Cells

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia Details Category: DNA RNA and Cells Published on Thursday, 16 September 2021 17:52 Hits: 130 NTLA-5001 is Intellia’s first ex vivo candidate using its proprietary cell engineering…

Continue Reading Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia | DNA RNA and Cells

FDA Approves First Human Trial for Potential CRISPR-Led HIV Cure

The first-in-human clinical trial for a candidate treatment for individuals living with human immunodeficiency virus type 1 is starting soon after its maker, Excision BioTherapeutics, today received an Investigational New Drug clearance from the U.S. Food and Drug Administration (FDA).  The FDA’s IND approval sets the stage for the very first Phase I/II…

Continue Reading FDA Approves First Human Trial for Potential CRISPR-Led HIV Cure

Beyond Ventures’ first investment, Prenetics, becomes first Hong Kong unicorn to go public

HONG KONG, Sept. 16, 2021 /PRNewswire/ — Hong Kong-based venture capital firm Beyond Ventures is pleased to support today’s announcement by the firm’s first investee company, Prenetics, that Prenetics, a global leader in genomic and diagnostic testing is set to merge with Artisan Acquisition Corp. (Nasdaq: ARTAU, “Artisan”), to become…

Continue Reading Beyond Ventures’ first investment, Prenetics, becomes first Hong Kong unicorn to go public

Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV | DNA RNA and Cells

Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV Details Category: DNA RNA and Cells Published on Wednesday, 15 September 2021 14:52 Hits: 247 EBT-101, first-in-human CRISPR-based one-time gene therapy to be evaluated in individuals with HIV Initiation of…

Continue Reading Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV | DNA RNA and Cells

The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Next-Generation Sequencing Utilizing Tumor Tissue and/or Blood The identification of actionable genomic alterations in tumors such as mCRC was once performed by Sanger DNA sequencing of tumor DNA that was extracted from fixed paraffin-embedded tumor tissue, but this has now been replaced by next-generation sequencing (NGS), which allows for larger-scale…

Continue Reading The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Dr. J. Curtis Nickel Urinary Microbiome Study Using MicroGenDX NGS Indicates Microbial Diversity Varies by Age and Gender | News

ORLANDO, Fla., Sept. 14, 2021 /PRNewswire-PRWeb/ — A study to help understand the implications of Next-Generation DNA Sequencing (NGS) in the diagnosis and treatment of Urinary Tract Infections (UTIs) and other inflammatory urological conditions has been completed, and results were presented at the September, 2021 AUA Conference. The study, a collaboration…

Continue Reading Dr. J. Curtis Nickel Urinary Microbiome Study Using MicroGenDX NGS Indicates Microbial Diversity Varies by Age and Gender | News

Dr. J. Curtis Nickel Urinary Microbiome Study Using MicroGenDX NGS Indicates Microbial Diversity Varies by Age and Gender

MicroGenDX Logo The study, a collaboration between Dr. J. Curtis Nickel and MicroGen Diagnostics, identified some 643 microbial species among 211 healthy subjects (106 female and 105 male) using NGS, with significant differences in microbial diversity based on gender, age, and previous antibiotic use. ORLANDO, Fla. (PRWEB) September 14,…

Continue Reading Dr. J. Curtis Nickel Urinary Microbiome Study Using MicroGenDX NGS Indicates Microbial Diversity Varies by Age and Gender

Twist Bioscience Corporation (TWST) has started shipping its synthetic RNA reference controls for the SARS-CoV-2 AY.1 and AY.2, more commonly known as Delta Plus

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has started shipping…

Continue Reading Twist Bioscience Corporation (TWST) has started shipping its synthetic RNA reference controls for the SARS-CoV-2 AY.1 and AY.2, more commonly known as Delta Plus

Colossal launches with $15 million to bring back woolly mammoths

Harvard scientist George Church, a pioneer of both DNA sequencing and gene editing, has been talking in the press for more than a decade about the possibility of bringing the extinct woolly mammoth back to life. It’s been the subject of magazine articles, books, and, of course, a TEDx talk….

Continue Reading Colossal launches with $15 million to bring back woolly mammoths

Tau t gromacs manual

Tau t gromacs manual TAU at TACC – TACC User PortalBiomolecules | Free Full-Text | Electrostatics of Tau GN Drive Tau | The Gundam Wiki | Fandom Kirk took a break and sent out for coffee when a patrolman brought him…

Continue Reading Tau t gromacs manual

Job vacancy in Global Worldwide: Bioinformatics Engineer at SAIC

Job details Salary $125,001 – $135,000 a year job type full-time Full job description Job id: 2112092 Location: college park , md , us Date posted: 2021-08-12 Category: engineering and sciences Subcategory: systems engineer Schedule: full-time Shift: day job Travel: no Minimum clearance required: public trust Clearance level must be…

Continue Reading Job vacancy in Global Worldwide: Bioinformatics Engineer at SAIC

Investors Pour $360 Million into Cutting-Edge Biotechs

After a quiet Labor Day weekend, four companies announced successful Series B raises to propel pipeline candidates further down the track toward clinical studies and approvals.   Cambridge-based Obsidian Therapeutics comes in with the highest raise of $115 million for its engineered cell and gene therapies. Led by TCGX, the round attracted both…

Continue Reading Investors Pour $360 Million into Cutting-Edge Biotechs

Japan in the Process of Selling GMO Fish

malias/wikimedia.com Japan is genetically modifying sea bream fish to have 50 percent more muscle and, according to Japan News/Yomiuri Shinbun, government approval is expected soon. Not surprisingly, there are concerns about what this will do to the environment and to consumers. To make the sea bream grow to have…

Continue Reading Japan in the Process of Selling GMO Fish

Dual Targeting of CDKN2A and PIK3CA May Offer Better Outcomes in Urothelial Carcinoma

Genomic testing varies in the academic and community setting. For community settings, commercial panels are available. However, academic settings have access to tools that provide a more comprehensive views of the genome. Investigators used patient-derived UC organoid (PDO) harboring FGFR3, PIK3CA, and CDKN2A mutations. Dose-response curves of alpelisib (Piqray), abemaciclib…

Continue Reading Dual Targeting of CDKN2A and PIK3CA May Offer Better Outcomes in Urothelial Carcinoma

Answers to commonly asked questions, KNEWS

As of July 2021, the coronavirus vaccine has been added to the National Vaccination Program for children and adolescents aged 12-17. Here are the most commonly asked questions and answers about the COVID-19 vaccine provided by the National Vaccination Committee. I hesitate to vaccinate my child because these vaccines…

Continue Reading Answers to commonly asked questions, KNEWS

Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives

DALLAS, Sept. 2, 2021 /PRNewswire/ — Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced the addition of two senior industry executives to support the Company’s clinical…

Continue Reading Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives

New Results from BabySeq, Pharmacogenomic Updates, New Products

September 1, 2021 | Harvard-Israel and Sema4-Avera launch precision medicine partnerships, Rice announces new Genetic Design and Engineering Center, Foundation Medicine partners with Epic, and Amgen and USC provide cryo-TEMs. Plus new products from BioIVT, BD.   Pluto Biosciences has launched its cloud-based, collaborative life sciences platform that leverages technology…

Continue Reading New Results from BabySeq, Pharmacogenomic Updates, New Products

Analysis of the Prognostic Significance of Circulating Tumor DNA in Metastatic Castrate Resistant Prostate Cancer

This article was originally published here Clin Genitourin Cancer. 2021 Jul 31:S1558-7673(21)00151-8. doi: 10.1016/j.clgc.2021.07.012. Online ahead of print. ABSTRACT BACKGROUND: There has been considerable interest in ctDNA next generation sequencing platforms to assess genomic alterations in mCRPC given its accessibility and identification of temporal genomic data. PATIENTSAND METHODS: In this…

Continue Reading Analysis of the Prognostic Significance of Circulating Tumor DNA in Metastatic Castrate Resistant Prostate Cancer

Rebecca Kneale Gould: In matters of life and death, reading the sources is critical

This commentary is by Rebecca Kneale Gould of Monkton, associate professor of environmental studies at Middlebury College. Two recent commentaries in VTDigger attempt to raise suspicions about vaccination, the No. 1 priority for our leaders managing the Covid crisis in Vermont.  Such commentaries demand further scrutiny, particularly because their authors…

Continue Reading Rebecca Kneale Gould: In matters of life and death, reading the sources is critical

Humane Genomics is 3D-printing oncolytic viruses to treat rare cancers

Oncolytic viruses have long held promise for cancer treatment, but their first generation hasn’t quite delivered. Armed with new tools and technology—including 3D printing—Humane Genomics is part of a wave of companies working on oncolytic viruses 2.0.  The only FDA-approved oncolytic virus is Amgen’s Imlygic, which scored a nod in…

Continue Reading Humane Genomics is 3D-printing oncolytic viruses to treat rare cancers

Emergence of the Coexistence of mcr-1, blaNDM-5, and blaCTX-M-55 in Kl

Introduction Klebsiella pneumoniae (K. pneumoniae) is an opportunistic pathogen and the leading cause of healthcare-associated infections.1 Multidrug-resistant (MDR) K. pneumoniae isolates are rapidly spreading, thus limiting the choice of antimicrobial agents for empiric treatment of infections caused by these microorganisms; hence, this is a public health challenge.2 Polymyxins are last-resort…

Continue Reading Emergence of the Coexistence of mcr-1, blaNDM-5, and blaCTX-M-55 in Kl

Vertex and Arbor Strike a $1.2 Billion Deal for Gene-Editing Programs

With a handful of drugs for cystic fibrosis already approved, Vertex Pharmaceuticals has turned its attention to expanding its pipeline through collaborations and acquisitions the past few years. Today, the California company announced a new agreement with an old partner. Nearly three years ago, Vertex and Arbor Biotechnologies struck a deal….

Continue Reading Vertex and Arbor Strike a $1.2 Billion Deal for Gene-Editing Programs

Irreversible Electroporation for Patients with Localised Prostate Cancer: Expert Opinion on this Versatile Therapeutic Approach

Interviewees: Olivier Cussenot,1 Phillip Stricker2,3,4 1. Department of Urology, APHP-Sorbonne University, Tenon Hospital, Paris, France2. Department of Urology, St Vincent’s Private Hospital and Clinic, Sydney, Australia3. Garvan Institute of Medical Research, Sydney, Australia4. Australian PC Centre, Sydney, Australia Disclosure: Cussenot is an expert for INCa (French National Cancer Institute) and…

Continue Reading Irreversible Electroporation for Patients with Localised Prostate Cancer: Expert Opinion on this Versatile Therapeutic Approach

It’s not easy to pronounce. But one thing is certain about FDA-approved Comirnaty: It works

The Food and Drug Administration on Monday issued full authorization for the Pfizer-BioNTech COVID-19 vaccine. Soon, millions of Americans will face a confusing, difficult task: How in the heck do you pronounce Comirnaty? That’s the brand name for the Pfizer-BioNTech COVID-19 vaccine. And it’s pronounced “co-MER-na-tee” according to Scott Piergrossi,…

Continue Reading It’s not easy to pronounce. But one thing is certain about FDA-approved Comirnaty: It works

Editas (EDIT) Up More Than 70% in Past 3 Months: Here’s Why

Shares of Editas Medicine, Inc. EDIT have rallied 78.7% in the past three months compared with the industry’s increase of 7.4%. Zacks Investment Research Image Source: Zacks Investment Research The company has made rapid progress in the development of its lead pipeline candidate, EDIT-101, in this time frame. EDIT-101 employs…

Continue Reading Editas (EDIT) Up More Than 70% in Past 3 Months: Here’s Why

The game has changed. The prize for winning? Life.

Sonya Addison, MD, is board-certified in Internal Medicine, Diabetes, Endocrinology, and Metabolism, and holds a certification by the American Society of Hypertension. She currently practices Endocrinology at Boone Medical Group Diabetes and Endocrinology in Columbia, Mo. This column is for educational and entertainment purposes, and is not meant to replace…

Continue Reading The game has changed. The prize for winning? Life.

Alumni of Chennai’s Sri Ramachandra Institute crowdsource Rs 44 lakh for lecturer’s treatment- The New Indian Express

By Express News Service CHENNAI: In a heartwarming gesture, alumni of Sri Ramachandra Institute of Higher Education and Research have joined hands to start a crowdfunding drive for the medical treatment of a lecturer who is suffering from a life-threatening illness. They have so far raised Rs 44 lakh out…

Continue Reading Alumni of Chennai’s Sri Ramachandra Institute crowdsource Rs 44 lakh for lecturer’s treatment- The New Indian Express

Kenya Targets Easing Sickle Cell Disease Pain Through Quality and Affordable Care

Health experts in Kenya aim to reduce the number of children born with sickle cell disease — an inherited blood disorder — by more than 12 times through public education and awareness, as the country premiered a guideline for controlling and managing the disease. The guideline titled Sickle Cell Disease…

Continue Reading Kenya Targets Easing Sickle Cell Disease Pain Through Quality and Affordable Care

Fact Check-mRNA vaccines are distinct from gene therapy, which alters recipient’s genes

Vaccines that use mRNA technology are not gene therapy because they do not alter your genes, experts have told Reuters after contrary claims were posted online. Thousands of social media users have shared such posts since the rollout of COVID-19 vaccines began (here) – and have continued to do so…

Continue Reading Fact Check-mRNA vaccines are distinct from gene therapy, which alters recipient’s genes